<DOC>
	<DOCNO>NCT02790944</DOCNO>
	<brief_summary>The primary objective study estimate prevalence germline mutation patient present consecutively within 12 week confirm diagnosis pancreatic ductal adenocarcinoma .</brief_summary>
	<brief_title>Utilizing Multi-gene Testing Approach Identify Hereditary Pancreatic Cancer</brief_title>
	<detailed_description>The propose research multi-site prospective observational plan investigate prevalence germline mutation patient diagnose pancreatic cancer . Thirty two gene analyze , associate increase risk cancer . The gene include CancerNextTM multi-gene next generation sequence array CGH test . The 32 gene include : APC , ATM , BARD1 , BRCA1 , BRCA2 , BRIP1 , BMPR1A , CDH1 , CDK4 , CDKN2A , CHEK2 , EPCAM , GREM1 , MLH1 , MRE11A , MSH2 , MSH6 , MUTYH , NBN , NF1 , PALB2 , PMS2 , POLD1 , POLE , PTEN , RAD50 , RAD51C , RAD51D , SMAD4 , SMARCA4 , STK11 , TP53 .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Male female patient age 18 89 year age . Diagnosed within previous 12 week histologically cytologically confirm PDAC Stage I IV . Ability participant understand willingness sign write informed consent document . Participant must agree sample collection genetic test use 32 gene test , CancerNextTM allow test result part medical record . Diagnosed intraductal papillary mucinous neoplasm , mucinous cystic neoplasm , pancreatic neuroendocrine tumor dysplasia without PDAC . Diagnosed PDAC 12 week present clinical site . Patients meet enrollment criterion CancerNext perform previously .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Germline</keyword>
	<keyword>Pancreatic</keyword>
	<keyword>Genetic Testing</keyword>
</DOC>